VRTX Vertex Pharmaceuticals Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRTX
  4. Earnings
?
Relative Growth: Rel. Growth: 77
Relative Strength: Rel. Strength: 42
Relative Valuation: Rel. Valuation: 61
Relative Profitability: Rel. Profitability: 99

EPS in 2025 (TTM): $14.31

Last Report Period Date: Sep 30, 2025

As of November 2025, VRTX's current EPS stands at $14.31, according to the latest financial reports. For the year 2024, the company recorded an earnings per share (EPS) of -$2.08, which marks a drop compared to its EPS of $14.05 in 2023. VRTX reported an EPS of $4.24 for the quarterly report ending on Sep 30, 2025.

VRTX earnings history

Historical annual and quarterly earnings per share (EPS) data for Vertex Pharmaceuticals
EPS (TTM)
$14.31
EPS Growth YoY (Quarterly)
4.7%
EPS (Quarterly)
$4.24
EPS Growth (Quarterly)
5.5%

For 2024, Vertex Pharmaceuticals's EPS was -$2.08, a drop of 114.8% from $14.05 in 2023. For the fiscal quarter that ended on Sep 30, 2025, the per-share earnings was $4.24, showing a 4.7% increase from the same quarter last year. For the twelve months ending September 2025, the EPS is $14.31. For the year 2023, the yearly earnings per share was $14.05, marking an increase of 8.3% from 2022.

VRTX EPS growth

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
4.7%
EPS growth YoY
-114.8%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

During the last 12 months, Vertex Pharmaceuticals has seen an EPS growth of 4.7% (YoY, quarterly).

VRTX Earnings Waterfall

Breakdown of revenue, profit and net income for Vertex Pharmaceuticals

VRTX Earnings vs Peers

What are the earnings of VRTX compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
MRK Merck & Co Inc 13.2 4,728.6% 9.4% 12%
BMY Bristol Myers Squibb Co 15.7 -213.7% N/A N/A
JNJ Johnson & Johnson 17.93 -57.9% -9.7% 0.4%
GILD Gilead Sciences Inc 24.44 -91.6% -57.5% -38.3%
VRTX Vertex Pharmaceuticals Inc 29.09 -114.8% N/A N/A
ABBV AbbVie Inc 164.69 -12.1% -28.2% -14.7%
ENTA Enanta Pharmaceuticals Inc N/A 14.1% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.